The Cholesterol Injection Given Every 6 Months: Explained

The injection is called inclisiran (brand name Leqvio), and it works by silencing a gene in the liver that drives up LDL cholesterol. After a starter dose and a follow-up at three months, you get one shot under the skin every six months, administered by a healthcare provider. In large trials, it cuts LDL cholesterol by roughly half, and that reduction holds steady for years. But the story behind how a twice-yearly injection can keep cholesterol low around the clock, who benefits from it, and what we still don’t know is worth understanding in detail.

How a Twice-Yearly Shot Lowers Cholesterol

Inclisiran belongs to a class of drugs called small interfering RNAs, or siRNAs. Rather than blocking a protein after it has already been made, inclisiran stops the protein from being produced in the first place. The target is PCSK9, a protein your liver makes that chews up LDL receptors on the surface of liver cells. Fewer LDL receptors means less LDL cholesterol gets pulled out of the bloodstream, which is bad news. By preventing PCSK9 from being manufactured, inclisiran lets more LDL receptors survive and do their job of clearing cholesterol from your blood.¹

The drug achieves this by binding to the messenger RNA that carries the instructions for making PCSK9 and flagging it for destruction. Once the messenger RNA is degraded, the liver cell can’t build the PCSK9 protein. The clever part is that inclisiran stays associated with the cellular machinery that does this work, so a single dose keeps silencing new copies of the messenger RNA for months.²

Why the Effect Lasts So Long

Most cholesterol drugs are cleared from your body within hours or days. Inclisiran’s extended duration comes from two design features. First, the drug is chemically linked to a sugar molecule called N-acetylgalactosamine (GalNAc). Liver cells have a receptor that specifically recognizes this sugar and pulls it inside, which means the drug goes almost exclusively to the liver rather than floating around the rest of the body.² This targeted delivery system has been validated across multiple drug programs; hepatocytes express the relevant receptor abundantly, making it a reliable way to get drugs into the liver.³

Second, once inside the liver cell, inclisiran binds tightly to the silencing machinery and stays there. Animal studies showed that after a single injection, the drug was retained in liver tissue long after it had disappeared from the bloodstream, which lines up with the twice-yearly dosing schedule used in patients.⁴ The practical upshot: your bloodstream sees the drug for only a short time, but the cholesterol-lowering effect persists for six months because the active machinery inside liver cells keeps working.

How Much It Actually Lowers Cholesterol

The headline numbers come from the ORION trial program. In the two pivotal phase 3 trials, ORION-10 and ORION-11, inclisiran reduced LDL cholesterol by about 50 to 53 percent compared to placebo at day 510, roughly a year and a half after the first dose.⁵ These patients were already on statins, so the reduction was on top of whatever benefit statins were providing.

Longer-term data look consistent. The ORION-3 extension trial followed patients for four years and found an average LDL cholesterol reduction of about 44 percent, sustained throughout the study period with PCSK9 levels staying suppressed by 62 to 78 percent.⁶ And ORION-8, the longest follow-up trial in the program, reported a roughly 49 percent reduction in LDL cholesterol at the end of the study, with similar numbers in patients with established cardiovascular disease.⁷ The consistency across these trials, spanning different populations and durations, is one of inclisiran’s strongest selling points. The LDL drop doesn’t fade with time the way adherence-dependent oral medications often do.

How It Compares to Other PCSK9-Targeting Drugs

Inclisiran is not the first drug to go after PCSK9. Two monoclonal antibody injections, evolocumab (Repatha) and alirocumab (Praluent), have been available since 2015. They work by grabbing PCSK9 protein in the bloodstream and preventing it from destroying LDL receptors. Inclisiran, by contrast, stops PCSK9 from ever being made. The end result is similar: both approaches reduce LDL cholesterol by roughly the same amount, around 50 percent on top of statins.⁸

The practical difference is dosing frequency. Monoclonal antibodies require an injection every two weeks or once a month, and patients self-inject at home. Inclisiran is given twice a year by a healthcare professional. That distinction matters more than it might seem. A network meta-analysis found no statistically significant difference in LDL-lowering between inclisiran, monoclonal antibodies, and the combination of a statin with ezetimibe.⁸ So the choice between these options often comes down to convenience, cost, and whether the patient prefers rare clinic-administered injections or frequent self-injections at home.⁹

The Adherence Advantage

Statin non-adherence is a well-documented problem. Within a year of starting, a large share of patients prescribed a daily statin stop taking it consistently. With injections every two weeks, monoclonal antibodies face their own adherence challenges. Inclisiran sidesteps much of this because the injection happens in a clinic, typically during a routine visit. You don’t have to remember to take it; you just have to show up.

Real-world data back this up. In a study tracking 225 patients who started inclisiran, about 92 percent returned for their second dose, and roughly 85 percent of those came back for their third.¹⁰ Those are high numbers for any chronic disease treatment. Researchers have noted that the infrequent dosing schedule likely plays a major role in keeping patients on track.

Real-world cholesterol reductions have matched expectations as well. In one clinic-based study, patients already on statins and ezetimibe who added inclisiran saw their LDL cholesterol drop from an average of 2.66 mmol/L to 1.49 mmol/L after the first dose, with about 73 percent reaching an LDL below 1.8 mmol/L.¹¹ The reductions held after the second dose. For patients who struggle to reach cholesterol targets on pills alone, this adds a powerful layer.

What About Heart Attacks and Strokes?

This is the biggest unanswered question, and it’s worth being direct about it. Inclisiran lowers LDL cholesterol convincingly. But lowering LDL is a surrogate endpoint, a stand-in for what patients actually care about: fewer heart attacks, strokes, and cardiovascular deaths. As of now, no completed cardiovascular outcomes trial has proven that inclisiran reduces those events.¹²

There are encouraging signals. A patient-level analysis pooling data from the phase 3 trials found that inclisiran was associated with a roughly 26 percent lower odds of major cardiovascular events compared to placebo over 18 months.¹³ That analysis covered about 3,600 patients, and while the composite endpoint was statistically significant, the reductions in heart attacks and strokes individually were not. The researchers themselves said these findings await confirmation in larger, longer trials. The ORION-4 trial (also called HPS-4/TIMI 65) is that confirmatory study, a large randomized trial designed to answer the cardiovascular outcomes question directly.

The broader scientific case for LDL lowering and cardiovascular benefit is strong; decades of research show that reducing LDL by any mechanism tends to reduce cardiovascular risk proportionally. But “tends to” is not the same as “proven for this specific drug.” The monoclonal antibody PCSK9 inhibitors have completed outcomes trials showing cardiovascular benefit. Inclisiran has not yet crossed that finish line. For some clinicians and patients, the strength of the LDL-lowering data and the class-level evidence are persuasive enough. Others want the outcomes trial results before committing.

Side Effects and Safety

In clinical trials, inclisiran’s safety profile has been fairly benign. The most commonly reported side effect is a reaction at the injection site: redness, pain, or swelling where the needle went in. This is typically mild and resolves on its own. Rates of serious adverse events have been similar between inclisiran and placebo groups across the ORION trials.¹⁴

Real-world surveillance is adding more detail. Two independent analyses of the FDA’s adverse event reporting database have flagged some signals worth watching. The most frequently reported events included joint pain, injection site pain, and muscle pain.¹⁵ One analysis also identified a handful of unanticipated signals that hadn’t been seen in clinical trials, including movement disorders, voice loss, and pulmonary congestion, though these were rare and the reporting database can’t prove the drug caused them.¹⁶ Adverse event databases capture signals that need further investigation; they don’t establish causation. Still, monitoring for new patterns is exactly what post-market surveillance is supposed to do.

For patients with mild or moderate liver impairment, studies have shown that inclisiran is generally safe and well tolerated, with no dose adjustment needed.¹⁷ Given that the drug works entirely in the liver, this was an important question to settle. Severe liver impairment has less data, and clinicians tend to be more cautious in that population.

Familial Hypercholesterolemia

One of inclisiran’s most important roles is in treating people with genetically high cholesterol. In the heterozygous form of familial hypercholesterolemia, where a person inherits one faulty copy of a gene involved in cholesterol clearance, inclisiran reduced LDL cholesterol by about 40 percent at day 510 in the ORION-9 trial. Across all the different genetic subtypes tested, the reductions were consistent.¹⁸

The homozygous form, where both copies of the gene are affected, is far rarer and harder to treat because these patients make very few functioning LDL receptors. In adults with homozygous familial hypercholesterolemia, the ORION-5 trial found that inclisiran cut PCSK9 levels by about 61 percent but did not produce a statistically significant drop in LDL cholesterol.¹⁹ This makes biological sense: if you barely have LDL receptors, suppressing PCSK9 won’t rescue many of them. The drug hits its biological target, but the downstream effect on cholesterol is blunted.

There’s a brighter note for younger patients. In adolescents with genetically confirmed homozygous familial hypercholesterolemia, the ORION-13 trial found a placebo-adjusted LDL reduction of about 33 percent, with most treated patients achieving meaningful cholesterol lowering and no serious adverse events.²⁰ Why adolescents might respond better than adults with the same condition isn’t fully understood, but the finding expands the potential patient population for this drug.

Cost and Accessibility

Inclisiran’s list price in the United States is around $3,250 per dose, which works out to about $6,500 per year after the loading period (two doses in the first year, then two per year ongoing). That is substantially less than the monoclonal antibody PCSK9 inhibitors cost when they first launched, though those prices have since come down with competition and rebates.

Health-economic analyses have found inclisiran to be cost-effective at various willingness-to-pay thresholds. In a U.S.-focused analysis, at the publicly available price of $3,250 per dose, inclisiran came in just above the $50,000-per-quality-adjusted-life-year threshold. At a threshold of $100,000 per QALY, the analysis found a 100 percent probability of cost-effectiveness when the annual price stayed below $9,000.²¹ Cost-effectiveness analyses from other countries have reached broadly favorable conclusions as well, including analyses from Chinese and Australian healthcare perspectives.²²²³

Insurance coverage varies. In the U.S., prior authorization is common, and most insurers require documentation that a patient has tried statins and possibly ezetimibe before approving inclisiran. In Europe, where inclisiran was approved for use in 2020 (a year before the U.S.), reimbursement criteria differ by country. For patients who qualify, the out-of-pocket cost can be minimal, but navigating the approval process often takes persistence from both the prescribing doctor and the patient.

Effects Beyond LDL Cholesterol

Because PCSK9 is involved in the metabolism of several lipid-related particles, inclisiran doesn’t just lower LDL cholesterol. Across the ORION trials, the drug has also reduced levels of apolipoprotein B and non-HDL cholesterol, both of which are considered important markers of cardiovascular risk.²⁴ There has also been interest in its effect on lipoprotein(a), a genetically determined particle that independently raises cardiovascular risk and is notoriously resistant to most existing therapies. The data on inclisiran’s effect on lipoprotein(a) have been examined in clinical trials, though the reductions reported for lipoprotein(a) tend to be modest compared to the substantial LDL cholesterol lowering.

For patients whose risk is driven partly by elevated apolipoprotein B or non-HDL cholesterol, the broader lipid-lowering profile makes inclisiran a more comprehensive intervention than a drug that only targets LDL. That said, the main reason to prescribe inclisiran remains LDL cholesterol reduction, and the additional lipid effects are a bonus rather than the primary rationale.

Where Gene Editing Might Take This Next

Inclisiran’s effect is powerful but temporary. Stop the injections, and PCSK9 production resumes within months. Researchers are already working on something more permanent: using gene editing tools to disable the PCSK9 gene entirely. Early animal studies using CRISPR-based editors have achieved durable, one-time reductions in LDL cholesterol in primates, and at least one human trial of a PCSK9 gene-editing therapy has begun. If those trials succeed, the concept of a twice-yearly cholesterol injection could eventually be replaced by a single treatment that lasts a lifetime.

That possibility is still years from clinical reality, and the safety bar for permanently altering someone’s genome is far higher than for a drug that wears off. Inclisiran currently occupies an interesting middle ground: it’s far more convenient than daily pills or biweekly injections, but it’s reversible in a way gene editing isn’t. For many patients and clinicians, that reversibility is actually reassuring. If an unexpected long-term side effect emerged, you simply stop the injections and the drug’s effect fades. A permanent genetic change doesn’t offer that exit ramp.